Serum response factor (SRF) regulates transcription of many serum-inducible and muscle-specific genes. Using a functional screen, we identified LIM kinase-1 as a potent activator of SRF. We show that SRF activation by LIM kinase-1 is dependent on its ability to regulate actin treadmilling. LIM kinase activity is not essential for SRF activation by serum, but signals depend on alterations in actin dynamics. Studies with actin-binding drugs, the actin-specific C2 toxin, and actin overexpression demonstrate that G-actin level controls SRF. Regulation of actin dynamics is necessary for serum induction of a subset of SRF target genes, including vinculin, cytoskeletal actin, and srf itself, and also suffices for their activation. Actin treadmilling provides a convergence point for both serum- and LIM kinase-1-induced signaling to SRF.
The mammalian target of rapamycin (mTOR) and Akt proteins regulate various steps of muscle development and growth, but the physiological relevance and the downstream effectors are under investigation. Here we show that S6 kinase 1 (S6K1), a protein kinase activated by nutrients and insulin-like growth factors (IGFs), is essential for the control of muscle cytoplasmic volume by Akt and mTOR. Deletion of S6K1 does not affect myoblast cell proliferation but reduces myoblast size to the same extent as that observed with mTOR inhibition by rapamycin. In the differentiated state, S6K1(-/-) myotubes have a normal number of nuclei but are smaller, and their hypertrophic response to IGF1, nutrients and membrane-targeted Akt is blunted. These growth defects reveal that mTOR requires distinct effectors for the control of muscle cell cycle and size, potentially opening new avenues of therapeutic intervention against neoplasia or muscle atrophy.
Signal-induced activation of the transcription factor serum response factor (SRF) requires alterations in actin dynamics. SRF activity can be inhibited by ectopic expression of -actin, either because actin itself participates in SRF regulation or as a consequence of cytoskeletal perturbations. To distinguish between these possibilities, we studied actin mutants. Three mutant actins, G13R, R62D, and a C-terminal VP16 fusion protein, were shown not to polymerize in vivo, as judged by two-hybrid, immunofluorescence, and cell fractionation studies. These actins effectively inhibited SRF activation, as did wild-type actin, which increased the G-actin level without altering the F:G-actin ratio. Physical interaction between SRF and actin was not detectable by mammalian or yeast two-hybrid assays, suggesting that SRF regulation involves an unidentified cofactor. SRF activity was not blocked upon inhibition of CRM1-mediated nuclear export by leptomycin B. Two actin mutants were identified, V159N and S14C, whose expression favored F-actin formation and which strongly activated SRF in the absence of external signals. These mutants seemed unable to inhibit SRF activity, because their expression did not reduce the absolute level of G-actin as assessed by DNase I binding. Taken together, these results provide strong evidence that G-actin, or a subpopulation of it, plays a direct role in signal transduction to SRF. INTRODUCTIONSerum response factor (SRF) is a transcription factor that regulates many immediate-early and muscle-specific genes. Deletion of SRF in ES cells leads to alterations in cellular morphology and adhesion, and is lethal in mice at gastrulation owing to defects in mesoderm formation (Arsenian et al., 1998;Weinhold et al., 2000;Schratt et al., 2002). SRF activity is controlled by the Rho family of small GTPases (Hill et al., 1995), and recent studies have revealed a close connection between SRF activation and actin polymerization. Downstream of RhoA, both the ROCK-LIMK-cofilin and the mDia effector pathways can promote both F-actin accumulation and SRF activity (Sotiropoulos et al., 1999;Tominaga et al., 2000;Copeland and Treisman, 2002;Geneste et al., 2002). The ability of LIMK and mDia mutants to activate SRF correlates with their ability to promote F-actin accumulation, and interfering derivatives of these proteins can inhibit the activation of SRF by extracellular signals (Sotiropoulos et al., 1999;Tominaga et al., 2000;Copeland and Treisman, 2002;Geneste et al., 2002). Alterations in actin dynamics are required for RhoA-mediated SRF activation, which is inhibited upon treatment of cells with the G-actin binding drug latrunculin or C2 toxin (Sotiropoulos et al., 1999). The RhoA-actin pathway controls a subset of SRF target genes, including the immediate-early genes -actin, vinculin, and srf, and the muscle-specific SM22 and SM ␣-actin genes (Sotiropoulos et al., 1999;Gineitis and Treisman, 2001;Mack et al., 2001).Several lines of evidence suggest that actin itself is intimately involved in the control o...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.